Have you assessed how the international operations of Charles River Laboratories (CRL Quick QuoteCRL - Free Report) performed in the quarter ended September 2026? For this medical research equipment and services provider, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.

In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.

Participation in global economies acts as a defense against economic difficulties at home and a pathway to more rapidly developing economies. However, it also comes with the complexities of dealing with fluctuating currencies, geopolitical risks and different market dynamics.

Upon examining CRL's recent quarterly performance, we noticed several interesting patterns in the revenue generated from its international segments, which are commonly analyzed and observed by Wall Street experts.

The recent quarter saw the company's total revenue reaching $982.73 million, marking a decline of 2.2% from the prior-year quarter. Next, we'll examine the breakdown of CRL's revenue from abroad to comprehend the significance of its international presence.

Unveiling Trends in CRL's International Revenues

Other International, including Brazil and Israel generated $18.73 million in revenues for the company in the last quarter, constituting 1.9% of the total. This represented a surprise of +71.7% compared to the $10.91 million projected by Wall Street analysts. Comparatively, in the previous quarter, Other International, including Brazil and Israel accounted for $13.12 million (1.3%), and in the year-ago quarter, it contributed $21.08 million (2.1%) to the total revenue.

During the quarter, Canada contributed $120.59 million in revenue, making up 12.3% of the total revenue. When compared to the consensus estimate of $116.84 million, this meant a surprise of +3.21%. Looking back, Canada contributed $127.51 million, or 12.7%, in the previous quarter, and $116.81 million, or 11.6%, in the same quarter of the previous year.

Of the total revenue, $240.13 million came from Europe during the last fiscal quarter, accounting for 24.4%. This represented a surprise of -5.38% as analysts had expected the region to contribute $253.77 million to the total revenue. In comparison, the region contributed $263.07 million, or 26.2%, and $277.69 million, or 27.6%, to total revenue in the previous and year-ago quarters, respectively.

Asia Pacific accounted for 6.3% of the company's total revenue during the quarter, translating to $61.63 million. Revenues from this region represented a surprise of +43.52%, with Wall Street analysts collectively expecting $42.94 million. When compared to the preceding quarter and the same quarter in the previous year, Asia Pacific contributed $60.52 million (6%) and $51.66 million (5.1%) to the total revenue, respectively.

International Market Revenue Projections

Wall Street analysts expect Charles River to report a total revenue of $963.94 million in the current fiscal quarter, which suggests a decline of 3.1% from the prior-year quarter. Revenue shares from Other International, including Brazil and Israel, Canada, Europe and Asia Pacific are predicted to be 1.4%, 12.2%, 26.7%, and 5.6%, corresponding to amounts of $13.62 million, $117.81 million, $257.61 million, and $53.94 million, respectively.

For the full year, the company is projected to achieve a total revenue of $3.92 billion, which signifies a fall of 2.3% from the last year. The share of this revenue from various regions is expected to be: Other International, including Brazil and Israel at 1.2% ($47.05 million), Canada at 12% ($471.72 million), Europe at 26.8% ($1.05 billion), and Asia Pacific at 5.4% ($212.88 million).

The Bottom Line

Charles River's reliance on international markets for revenues offers both opportunities and risks. Hence, keeping an eye on its international revenue trends could significantly help forecast the company's prospects.

In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.

At the moment, Charles River has a Zacks Rank #3 (Hold), signifying that its performance may align with the overall market trend in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

A Review of Charles River Laboratories' Recent Stock Market Performance

The stock has increased by 11.8% over the past month compared to the 5.6% fall of the Zacks S&P 500 composite. Meanwhile, the Zacks Medical sector, which includes Charles River,has increased 9.4% during this time frame. Over the past three months, the company's shares have experienced a gain of 20.5% relative to the S&P 500's 4.1% decline. Throughout this period, the sector overall has witnessed a 8% increase.